Received May 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | UNK | — | — |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | UNK | — | — |
no symptomatic, no additional AE; report administrations of VARIVAX and PROQUAD on 05/02/2026 for 13-month-old twin patients.; HCP calling to report administrations of VARIVAX and PROQUAD for 13-month-old twin patients. Patients are not symptomatic; This spontaneous report was received from a Nurse and refers to 13-months old patient of unknown gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 02-MAY-2025, the patient was vaccinated with a dose of Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD), (lot # and expiration date were not reported); along with Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX), (lot # and expiration date were not reported) diluted with sterile diluent (MERCK STERILE DILUENT) (lot # and expiration date were not reported); all vaccines were administered for prophylaxis (inappropriate schedule/ accidental overdose). The patient was asymptomatic, and no additional adverse event was reported. This is one of 2 reports from the same reporter.
Sterile diluent